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Quantitative PCRThe mitochondrial phospholipid cardiolipin plays an important role in cellular metabolism as exempliﬁed by
its involvement in mitochondrial energy production and apoptosis. Following its biosynthesis, cardiolipin is
actively remodeled to achieve its ﬁnal acyl composition. An important cardiolipin remodeling enzyme is
tafazzin, of which several mRNA splice variants exist. Mutations in the tafazzin gene cause the X-linked
recessive disorder Barth syndrome. In addition to providing an overview of the current knowledge in
literature about tafazzin, we present novel experimental data and use this to discuss the functional role of the
different tafazzin variants in cardiolipin metabolism in relation to Barth syndrome. We developed and
performed speciﬁc quantitative PCR analyses of different tafazzin mRNA splice variants in 16 human tissues
and correlated this with the tissue cardiolipin proﬁle. In BTHS ﬁbroblasts we showed that mutations in the
tafazzin gene affected both the level and distribution of tafazzin mRNA variants. Transient expression of
selected human tafazzin variants in BTHS ﬁbroblasts showed for the ﬁrst time in a human cell system that
tafazzin lacking exon5 indeed functions in cardiolipin remodeling.
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Tafazzin mutations of the BTHS ﬁbroblasts used.
BTHS patienta Mutationb Protein
TAZ001 c.153CNG p.Tyr51X
TAZ002 c.239-1GNA AGNAA r.spl. Ex3del?
TAZ003 c.170GNT p.Arg57Leu
TAZ005 – –
TAZ006 c.170GNT p.Arg57Leu
TAZ007 – –
TAZ009 – –
TAZ010 c.590GNT p.Gly197Val
TAZ011 c.280CNT p.Arg94Cys
TAZ012 – –
TAZ013 c.110-1GNC AGNAC r.spl. Ex2del?
TAZ014 – –
a All patients were diagnosed with BTHS on the basis of (ML)CL analysis.
b Tafazzin mutations were not determined for all BTHS patients.1. Introduction
Cardiolipin (CL) is a phospholipid that, at least in eukaryotes, is
primarily localized to the mitochondrial membranes. In contrast to
other phospholipids CL has four acyl chains which are linked to a
backbone of three glycerol moieties. Because of this unique composi-
tion CL can adopt a speciﬁc conical structure, which is important for
membrane curvature. In the mitochondrial membrane CL has several
specialized functions, especially in energy production and mitochon-
drial apoptosis. CL is synthesized from its precursors phosphatidyl-
glycerol (PG) and cytidinediphosphate-diacylglycerol (CDP-DAG) and
after primary synthesis CL acyl chains are remodeled to achieve its
ﬁnal mature composition. To exert its function properly, it is essential
that CL is present in this mature form, as illustrated by the
mitochondrial disorder Barth syndrome, which is caused bymutations
in the tafazzin gene encoding a CL remodeling enzyme. In this review
we will discuss the composition of CL in relation to CL function,
analytical methods for measurement of CL, and focus on Barth
syndrome (BTHS) with emphasis on the function of the tafazzin. In
addition to providing an overview of current knowledge in literature,
we will provide experimental evidence to illustrate our views on the
role of tafazzin in CL metabolism.
2. Materials and methods
2.1. CL analysis in human tissues
Anonymized human postmortem frozen tissue samples were
obtained from the NICHD Brain and Tissue bank for Developmental
Disorders at the University of Maryland. Tissues were homogenized in
PBS using an Ultra-Turrax homogenizer and sonicated for 20 s using a
tip sonicator. The protein concentration was determined according to
the Bradford protocol [65]. Phospholipids were extracted using a 2-
phase extraction [31]. The HPLC–MS systemwas operated as described
previously [18]. For quantiﬁcation of CL and MLCL levels, the area
under the curve of the HPLC proﬁle corresponding to the mass spectra
of CL and MLCL species was integrated, as well as that of the internal
standard. CL concentration was calculated based on the internal
standard, assuming identical response.
2.2. Tafazzin mRNA tissue distribution
Tissue distribution of human tafazzin splice variants was analyzed
in an MTC human tissue cDNA panel (Clontech). Speciﬁc primer sets
were developed for the different human tafazzin splice variants by
using speciﬁc combinations of exon–exon boundaries (for primer
sequences see Table 1). For the quantitative real-time PCR the
LightCycler 480 SYBR Green I Master kit (Roche) was used. The
amount of cDNA in the individual samples of the cDNA panel was
normalized for a combination of four housekeeping genes (α-tubulin,
β-actin, glyceraldehyde-3-phosphate dehydrogenase, phospholipase
A2), as described by the manufacturer. All samples were analyzed in
triplicate. The data were analyzed using linear regression calculations
as described previously [66].
2.3. Tafazzin mRNA analysis in control and BTHS ﬁbroblasts
Total RNA was isolated from control and BTHS ﬁbroblasts using
Trizol extraction. cDNA was produced using a ﬁrst-strand cDNAsynthesis kit. Real-time PCR and linear regression calculations were
performed as described above. Speciﬁc primer sets were used for
“total tafazzin” (i.e. all variants ampliﬁed together) and for all the
distinct tafazzin variants (see Table 2). Cyclophilin was used as a
housekeeping gene to adjust for variations in the amount of input
RNA. Sequence analysis of the ampliﬁed PCR product conﬁrmed that
the primer sets were speciﬁc for the particular mRNA variants. As an
additional control for PCR efﬁciency, we ampliﬁed the various tafazzin
variants from a pool of linearized plasmids containing an equal
amount of each of the different variants and showed that PCR
efﬁciency was virtually identical for all variants. All samples were
analyzed in triplicate.
2.4. Yeast complementation analysis
Expression of tafazzin variants in wild type (w303) and tazΔ yeast
was performed as described previously [31]. The improved HPLC–MS
analysis was performed as described in [18].
2.5. Transient tafazzin expression
The various tafazzin cDNAs were cloned in pcDNA3 and
transfected to control and BTHS ﬁbroblasts using the Amaxa
electroporation procedure (Amaxa). As a control, we transfected
control and BTHS ﬁbroblasts with the empty vector. In short, 2 μg of
plasmid was transfected to 500,000 cells, for each condition we
performed 10 transfections in parallel, which were pooled after the
electroporation. After 48-h culture on normal culture medium
(DMEM+10% FCS), cells were shifted to medium containing
resistance selection marker (100 μg/mL G-418 in DMEM+10%
FCS) and were cultured for additional 8 days with regular changing
of the selective medium and shift to larger culture ﬂasks when
necessary. Ten-day post-transfection cells were harvested by
trypsinization. The resulting cell pellet was homogenized in PBS,
sonicated for 20 s using a tip sonicator and protein concentration
was determined using the Bradford protocol. The equivalent of 40 μg
of protein was used for SDS-PAGE followed by immunoblotting
using the crude serum of a rabbit that was immunized with C-
terminal 100 amino acids of human tafazzin (a kind gift of Dr. A.
Metzenberg). The remaining cell suspension (∼300 μg) was used for
CL analysis as described previously [29].
Fig. 1. Biosynthesis and remodeling of CL. CDP-DAG, the branch point in phospholipid
biosynthesis, is formed by condensation of CTP and PA. In the dedicated PG and CL
pathway, CDP-DAG is converted to PGP by the enzyme PGP synthase, and PGP
subsequently is dephosphorylated by a phosphatase yielding PG. In the ﬁnal step of CL
biosynthesis condensation of one molecule of PG and one molecule of CDP-DAG by the
enzyme CL synthase results in the formation of immature CL. In order to obtain mature
CL (tetralinoleoyl-CL in case of humans), acyl chain remodeling occurs either by
deacylation–reacylation or by transacylation. The deacylation–reacylation reaction or
Lands cycle involves phospholipase-mediated deacylation and acyltransferase-
mediated reacylation.
Table 2
Primer-sets used for speciﬁc ampliﬁcation of tafazzin splice variants.
TAZ variant Forward primera Reverse primera Bpb
HTAZ total exon3/4 exon9 407
5′-CTG AAG TTG ATG CGT TGG ACC-3′ 5′-GGA-CTG-TTA-GGA-AGG-ACG-TC-3′
HTAZ full length exon5/6 exon6/7 102
5′-AGA GAA AGG AGA TGG CGT CT-3′ 5′-ATG TTC ACT TTC CCT TCT GGG-3′
HTAZ-ex5 exon4/6 exon6/7 102
5′-GTG CCG AGG AGA TGG CGT C -3′ 5′-ATG TTC ACT TTC CCT TCT GGG-3′
HTAZ-ex7 exon5/6 exon6/8 96
5′-AGA GAA AGG AGA TGG CGT CT-3′ 5′-CGA TTC CTT CTG GGA AGA TAT G-3′
HTAZ-ex5/7 exon4/6 exon6/8 100
5′-GTG CCG AGG AGA TGG CGT C-3′ 5′-CGA TTC CTT CTG GGA AGA TAT G-3′
HTAZ-ex6/7 exon3/4 exon5/8 201
5′-CTG AAG TTG ATG CGT TGG ACC-3′ 5′-CCC GAT TCC TTT CTC TCT TC-3′
HTAZ-ex5/6/7 exon3/4 exon4/8 111
5′-CTG AAG TTG ATG CGT TGG ACC-3′ 5′-CCC GAT TCC TCG GCA CAC A-3′
a For each primer the exon–exon boundary is indicated as well as the primer sequence.
b Bp shows the length of the ampliﬁed PCR fragment.
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CL is an important constituent of the mitochondrial membrane of
eukaryotes. It is primarily found in the innermitochondrial membrane
and to a lesser extent also in the outer mitochondrial membrane [1].
During certain processes, notably mitochondrial apoptosis, CL is
translocated to the outer membrane and/or clusters at contact sites
between the outer and inner membranes [2]. At the contact sites, CL is
thought to serve as a platform for proteins involved in apoptosis,
thereby bringing several components of this machinery together [3,4].
Besides this role in cell death, CL is also an important molecule
required for the optimal functioning of the respiratory chain. Several
of the proteins of the respiratory chain have been reported to bind to
CL or require CL for optimal activity (as reviewed in [5]). Furthermore,
CL is reported to function in the stabilization of the individual
respiratory chain complexes in a larger so-called supercomplex
enabling efﬁcient channeling of electrons through the complexes
[6–8]. In a recent paper, Claypool et al. have provided evidence to
show that the mitochondrial ATP/ADP carrier, which is known to
require CL for optimal activity [9], is also incorporated into a CL-
dependent supercomplex containing complexes III and IV in Sac-
charomyces cerevisiae [10]. The same group also showed that yeast
tafazzin interacts with multiple proteins among which ATP synthase
and the aforementioned ATP/ADP carrier [11]. Finally, the speciﬁc CL
headgroup is thought to enable trapping of protons in the intermem-
brane space, thereby increasing the efﬁciency of the channeling of the
protons back into the mitochondrial matrix by the ATP synthase
complex [12]. For a more detailed review of CL function we
recommend the following literature [5,13,14].
Recently, abnormal CL levels or composition have been linked to
common diseases such as diabetes and heart failure. We will not focus
on these aspects of CL and refer the reader to [5,15].
3.1. CL synthesis and remodeling
CL is synthesized in the mitochondrion from PG and CDP-DAG and
this process has been described in detail elsewhere [5,14,16]. Brieﬂy,
CDP-DAG is converted to phosphatidylglycerolphosphate (PGP) by the
enzyme PGP synthase, and PGP is dephosphorylated by a phosphatase
yielding PG. In the ﬁnal step of CL biosynthesis, condensation of one
molecule of PG and one molecule of CDP-DAG by the enzyme CL
synthase results in the formation of CL (Fig. 1). Importantly, the
mature acyl chain composition of CL is not explained by the substrate
speciﬁcity of CL synthase [17–19], which implies that additional
mechanisms are involved in achieving the ﬁnal composition by acyl
chain remodeling. Remodeling of phospholipid acyl chains can occur
either by a deacylation–reacylation cycle, i.e. the Lands cycle [20],or by transacylation [21]. The Lands cycle for CL comprises a
phospholipase-mediated deacylation forming monolyso-CL (MLCL)
followed by a CoA-dependent reacylation. Several enzymes have been
described that are capable of performing this reaction, and all these
enzymes showed preference for acyl-CoA species that are typically
found in mature CL [22–24]. CoA-independent transacylation of CL
occurs by the transfer of an acyl chain from phosphatidylcholine (PC)
to MLCL forming lyso-PC and CL [21]. This enzymatic activity was
characterized in rat liver and human lymphoblasts and was shown to
be speciﬁc for linoleoyl-containing PC [21]. The same group also
demonstrated that D. melanogaster tafazzin, which in humans is the
enzyme deﬁcient in BTHS patients, also functions as a transacylase in
CL metabolism by transferring a linoleic acid group from PC to MLCL,
thereby enriching CL with this speciﬁc acyl chain [25]. A more detailed
overview on the current state of knowledge on tafazzin will be
provided below.
Fig. 2. Typical HPLC–MS spectra of (ML)CL in control and BTHSmuscles. CL in control muscle is highly enriched in linoleic acid acyl chains, as demonstrated by the high abundance of
tetralinoleoyl-CL (m/z 723). MLCL levels in control muscle are very low. In BTHSmuscle, CL levels are decreased and amore diverse pattern of CL species is observed (smaller clusters
of CL around m/z 687, 700, 714). The MLCL levels are highly increased in BTHS muscle. CL i.s.=CL internal standard (tetramyristoyl-CL).
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BTHS (MIM 302060) is an X-linked recessive disorder, clinically
characterized by the classical symptoms (cardio-)myopathy, neutro-
penia and growth delay [26,27]. BTHS is caused by mutations in the
tafazzin gene [28], located at Xq28. As a result of the tafazzin
mutations, the remodeling of CL is hampered and BTHS cells therefore
show an abnormal CL proﬁle [29–34]. CL levels in tafazzin-deﬁcient
(i.e. BTHS) cells are lower, MLCL levels are markedly elevated and the
acyl chain composition is shifted toward less unsaturated species (Fig. 2).
These biochemical abnormalities have been proven to be very useful in
the diagnosis of BTHS, especially the MLCL/CL ratio has been shown to
be a very sensitive and speciﬁc parameter [30,34,35]. The development
of a bloodspot screening method [35] together with conﬁrmatory tests
in tissues including lymphocytes, ﬁbroblasts and muscle [34] has
completed the diagnostic palette for BTHS allowing low threshold
screening for this disorder. The diagnostic analysis of BTHS should
therefore primarily be based on these analyses (Fig. 3), and not solely on
the measurement of 3-methylglutaconic acid in urine as an increased
excretion is not observed in all patients [36] and is not speciﬁc for BTHS
[37]. As depicted in Fig. 3, we advocate a ﬂowchart for the diagnosis of
BTHS involving the low threshold bloodspot method, followed by
conﬁrmation in either lymphocytes or ﬁbroblasts and ﬁnally, if both are
positive, tafazzin mutation analysis.
As a result of the CL and MLCL abnormalities, mitochondria of
tafazzin-deﬁcient cells show abnormal cristae formation [26,38] and
pathways which rely on properly formed CL are impaired [3,7,8]. How
the reported functions of CL inﬂuence the pathophysiology of BTHS is
matter of research in multiple laboratories, but remains unclear. It
seems plausible that the impaired respiratory chain function couldFig. 3. Flowchart for diagnostic analysis of BTHS. Broad inclusion criteria should be applied f
quantiﬁcation of the MLCL/CL ratio in a bloodspot should be performed, which, if sugges
lymphocytes or ﬁbroblasts. If again suggestive for BTHS, genetic analysis should be used toresult in (cardio-)myopathy, since the energy demand of these tissues
is high, which requires high levels of ATP synthesis. Inmarked contrast
to what one would expect on the basis of this hypothesis, central
nervous system pathology is not observed in BTHS patients, in
contrast to (most) inherited respiratory chain disorders [39,40].
Furthermore, it is unlikely that the neutropenia of BTHS patients is
caused by impaired respiratory chain function because neutrophils are
mostly glycolytic [41]. Further studies are needed to clarify the
pathological mechanisms in these speciﬁc tissues and/or cell types. It
would also be very interesting to investigate which additional factors
play a role in modifying the phenotype of BTHS patients, since
mutations in the tafazzin gene do not correlate with the disease
severity, even within one family [42].
3.3. CL composition in human tissues
As suggested by its name, CL is very abundant in heart, the organ
where it was ﬁrst isolated from [43]. In human heart, but also in other
tissues, tetralinoleoyl-CL is the predominant species [44] (Fig. 4A). In
other organisms, such as S. cerevisiae or marine bivalves, other acyl
chains, i.e. oleic acid and docosahexaenoic acid respectively, are
predominantly incorporated in CL [45]. Although the speciﬁc species
of CL are different between organisms, it appears that there always is a
high degree of structural symmetry in CL [45], suggesting that
throughout evolution this uniformity is important for CL function.
Because little information is available on the CL distribution in
human tissues and on the variation between individuals, we set out to
investigate the CL proﬁle in different human tissues. In addition, we
aimed to correlate these data with expression levels of the human
tafazzin splice variants, as will be discussed below.We analyzed the CLor consideration of BTHS diagnostic analysis. Initially, low threshold measurement and
tive for BTHS, should be followed by more detailed analysis of the (ML)CL proﬁle in
conﬁrm the diagnosis by tafazzin mutation analysis.
Fig. 4. Tissue distribution of CL. (A) CL abundance in various tissues. Each symbol represents the tissue of a single individual. (B) Distribution of various CL clusters. Clusters are
indicated as the number of carbon atoms in the combined acyl chains (e.g. C70 represents all CL species which have 70 carbon atoms in the acyl chains, most likely 3×C18 and
1×C16). Individual clusters were quantiﬁed and the relative abundance to the highest cluster (C72) is shown. In brain, a more diverse pattern is observedwith more CL clusters and a
relatively high abundance. Data are means±standard deviation. Number of samples is as shown in (A). (C) Comparison of CL proﬁle of human heart and brain. Human heart
effectively contains only one CL species, whereas brain CL acyl chain composition is more diverse and also contains more polyunsaturated fatty acids such as arachidonic and
docosahexaenoic acids.
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composition of CL. As shown in Fig. 4A, the heart is especially rich in
CL. Tissues such as spleen, adipose tissue and pancreas showed lower
CL levels and other tissues displayed considerable variation in CL
levels between investigated individuals (kidney and brain). One of the
main advantages of the HPLC–MS for the measurement of CL is thatone can discriminate between the different species of CL. Therefore,
we quantiﬁed the abundance of the various CL clusters (each cluster is
represented by the number of carbon atoms in the combined acyl
chains) in relation to the highest cluster (i.e. C72, most likely 4×C18).
Heart and skeletal muscle, tissues that require high mitochondrial
metabolic activity, contained mainly tetralinoleoyl-CL (part of the C72
2008 R.H. Houtkooper et al. / Biochimica et Biophysica Acta 1788 (2009) 2003–2014cluster) whereas the other CL species were less abundant (Fig. 4B).
Although other tissues showed more variation in cluster abundance,
the C72 cluster was clearly the highest and only three other clusters
could be detected (C68, C70 and C74). In brain, however, the CL
pattern was completely different as compared to other tissues (Fig.
4C). There are at least seven CL clusters (C66 to C78) where the
species distribution, as judged from the broadness of the clusters, is
considerably greater than in other tissues. The high molecular weight
clusters (C74 to C78) contain increasing amounts of polyunsaturated
fatty acids like arachidonic and docosahexaenoic acids. A theory that is
worth mentioning here is that the tissue-speciﬁc CL composition
reﬂects the speciﬁc metabolic needs of a tissue, as suggested by Cheng
et al. [46], who also recently investigated the CL proﬁle of (mouse)
brain. According to this hypothesis one would expect that in tissues
that have high mitochondrial activity, e.g. heart and liver, CL is
specially suited for optimizing this activity, whereas in tissues where
CL is not crucial for maintaining high mitochondrial function, e.g. the
brain that relies mostly on glucose, its CL composition does not need
speciﬁc adaptation to tetralinoleoyl-CL and is more diverse. This
theory should be explored further, along with the possibility that the
diverse CL pattern in brain has a speciﬁc, yet unknown, function.
The lack of highly structured CL composition in brain and the
hypothesis that this is not essential for mitochondrial function in brain
might also explain why BTHS patients do not suffer from brain
abnormalities, since disturbances of the CL composition by tafazzin
deﬁciency are less severe for brain CL than for CL in tissues that
predominantly have the highly symmetric (i.e. heavily remodeled)
tetralinoleoyl-CL.
3.4. CL analysis
The available techniques for the identiﬁcation and quantiﬁcation of
CL have been reviewed recently [47]. Beside the relatively insensitive,
seldom used, 31P-NMR measurement, these techniques comprise of
methods based on one/two-dimensional TLC spot isolation followed
by either colorimetric detection of total phosphate after hydrolysis or
by detection of the fatty acid methyl esters of the methanolic HCl
hydrolysate. Alternatively, HPLC fractionation of a phospholipid
extract can be employed followed either by UV detection, ﬂuorescence
detection (after derivatization), scintillation counting (in case of
radioactive species) or immunological detection of cardiolipin [47].
The main drawbacks of these methods are an extensive sample
preparation and/or their limitations in speciﬁcity and sensitivity. The
requirements of the study and the availability of equipment may
direct the choice to one of these methods. At present, however, MS
instrumentation can combine high sensitivity, high selectivity and
structural information with a rapid sample preparation. For these
reasons, it has become the analytical method of choice for many
applications.
In general, the LC–MS methods have a sample preparation that is
based on a simple methanol/chloroform extraction of the lipids
[48,49] after which the crude sample is injected into the LC–MS
system [50]. Electrospray ionization (ESI) is the most widely used
ionization method, but to a lesser extent, without hyphenation (i.e.
coupling to a pre-MS separation technique), matrix-assisted laser
desorption/ionization (MALDI) and desorption electrospray ioniza-
tion (DESI) are also used as ionization methods.
Roughly, the MS-basedmethods for the determination of CL can be
differentiated according to the extent of hyphenation, MS multiplicity
(MSn) and mass resolution.
The potential of application of the MS approach without
hyphenation has been clearly demonstrated by Han and Gross,
elaborating on the so-called shotgun lipidomics technique [51]. By
virtue of adjustment of solvent composition (mainly pH) to enhance
“intrasource” separation either with or without pre-selected MS/MS
scans, suppression effects and interference of isobaric componentscan be reduced. In addition, high mass resolution allows for m/z peak
separation of the doubly charged CL species. Although the method is
fast, the main drawback of the technique is the unpredictable amount
of interfering components in the resulting composite spectra.
For qualitative or semi-quantitative purposes, LC–MS techniques
are available. HPLC–MS methods with reversed or normal phase
columns are used to separate CL from other efﬁciently ionizing
(phospho)lipids. The power of HPLC to separate CL from other
phospholipids results in the sensitive measurement of pure, char-
acteristic CL proﬁles (as shown in Figs. 2, 4C and 7).
Quantitation of a large range of CL molecular species using an LC–
MS approach, identifying CLs by the number of carbon atoms and the
degree of unsaturation of the acyl chains, has been described
previously [50,52]. Whether they use the singly [52] or doubly
charged molecular species [50], the exact molecular structure of the
CL (i.e., the exact location and identity of the four acyl chains) cannot
be determined, although LC–MS/MS analysis of the precursor ions can
provide a qualitative indication of the predominant fatty acyl chain
composition within the mixture. In all cases the use of a set of
synthetic CL standards, in combination with a mathematical correc-
tion for overlapping isotopic peaks of different molecular species, is a
prerequisite for accurate quantitation [50]. Quantitation using an
HPLC–MS setup is hampered, however, by the fact all CL species show
a different analytical response (depending on the number of carbon
atoms and double bonds in the acyl chain). Since the added synthetic
standards (generally tetramyristoyl-CL) have a different composition
compared to the analyzed CL species, pure quantitative data cannot be
obtained although semi-quantitative analysis is possible.
Full characterization of the CL species in a biological mixture,
including species that consist of various isomers can only be achieved
in detail by (at least) MS3 using ion trap technology [53]. The
differentiation of CL isomers and the identiﬁcation of complex CL
species consisting of multiple molecular structures, however, require
highly specialized instruments which are seldom available for routine
CL analyses.
4. Tafazzin
4.1. Tafazzin gene, mRNA and protein
Asmentioned above, mutations in the tafazzin gene (TAZ, originally
termed G4.5) result in the rare X-linked recessive disorder BTHS [28].
The Italian group that identiﬁed the tafazzin gene named it after a
masochistic comic character from an Italian television sports show
and the gene/protein has lived up to this masochistic character, as
experienced by many researchers working on this subject. One of the
complicating aspects of tafazzin research is the alternative splicing of
the primary transcript resulting in different mRNAs and potentially
different proteins [28]. As will be discussed below in more detail,
expression of these different splice variants in tafazzin-deﬁcient yeast
(tazΔ) showed that only the human tafazzin variant lacking exon5was
able to fully restore the aberrant CL proﬁle of the tazΔ mutant. The
full-length tafazzin variant only partially restored the CL proﬁle [31].
Protein sequence alignment suggested that exon5 in human tafazzin
was actually introduced later in evolution since it is not found in
tafazzin of lower organisms [31]. This idea was conﬁrmed by tafazzin
gene analysis which showed that the exon5 sequence was present in
all monkey species tested, but that the splice recognition site for exon5
was only present in primates yielding incorporation into the mRNA
[54]. Because the CL composition in primates (i.e. which have mRNA
transcripts containing exon5) and other mammals (i.e. which lack
exon5) is identical and because the full-length human tafazzin was
unable to fully restore the CL proﬁle of tazΔ yeast, it is important to
determine the function of this full-length variant with respect to CL
metabolism. It is relevant to note that recently BTHS patients have
been found with a mutation in exon5 (“Human Tafazzin (TAZ) Gene
2009R.H. Houtkooper et al. / Biochimica et Biophysica Acta 1788 (2009) 2003–2014Mutation and Variation Database”; www.barthsyndrome.org). Theo-
retically, these patients should have normal levels of the tafazzin
variant lacking exon5 if the mutation does not lead to instability and/
or degradation of the primary transcript. It would be very interesting
to investigate the expression of the different tafazzin mRNA variants
and more importantly the levels of CL and MLCL in these patients.
4.2. Tafazzin mRNA expression—human tissue distribution
One of the remaining questions is which of the tafazzin splice
variants are functionally signiﬁcant in vivo. The preferred method to
check whether the variants are actually expressed in cells/tissues is
obviously by protein detection using a tafazzin-speciﬁc antibody,
however, until now it has proven to be impossible to detect
endogenous levels of this protein. A second option is to investigate
mRNA expression of the different variants. The original identiﬁcation
of the alternatively spliced tafazzin transcripts was based on regular
PCR analysis on total RNA of ﬁbroblasts, heart, skeletal muscle and
leukocytes [28] and was conﬁrmed in ﬁbroblasts in a later study [54].
Because regular PCR is not suited for quantitative comparison of the
different variants, especially when different primer-sets are used, we
used quantitative PCR on human tissue cDNA. Logically, one would
expect that tafazzin expression is highest in tissues that require high
levels of linoleic acid incorporation in CL and that are affected in BTHS
patients, such as heart and skeletal muscle. According to this rationale,
the expression of the proposed (semi-) active variants, i.e. full-length
tafazzin and tafazzin lacking exon5, is expected to be highest in these
tissues. Using variant-speciﬁc primers we analyzed expression levels
of 6 different tafazzin splice variants in 16 different human tissues
(Fig. 5). To our surprise, we found that in all investigated tissues all
tafazzin variants were more or less equally expressed with the
exception of tafazzin lacking exon6,7, which was very low. Unexpect-
edly, we found that the highest tafazzin expression was observed in
pancreas and spleen, whereas expression levels of the different
tafazzin variants in heart and muscle was in the same range as
compared with other tissues. Interestingly, these data do not correlate
with the observed CL proﬁle of the various tissues (Fig. 4). Themarked
enrichment of heart, skeletal muscle and liver CL with linoleic acid is
apparently not due to increased tafazzin mRNA expression. Con-
comitantly, higher tafazzin expression as observed in pancreas and
spleen does not result in higher tetralinoleoyl-CL abundance. On the
contrary, the CL composition of spleenwas considerablymore variable
than that of heart. Obviously, this discrepancy could be caused by the
fact that mRNA levels do not necessarily reﬂect protein levels,
however, given the absence of an antibody that detects endogenous
tafazzin protein(s), quantitative mRNA levels currently are the best
available indicator of tafazzin expression. As will be discussed below,
another important factor that likely inﬂuences the tafazzin-mediated
CL remodeling toward mature CL is the nature and direct availability,
i.e. the microenvironment, of substrates for tafazzin. For example,
brain expression of tafazzin mRNA was among the lowest of the
investigated tissues (Fig. 5). This could explain the diverse CL species
distribution that was observed in this tissue (Fig. 4B and C), but the
different CL proﬁle may also be attributed to the speciﬁc microenvir-
onment of the brain (i.e. the high levels of arachidonic and
docosahexaenoic acid) and therefore could be relatively independent
of tafazzin expression. How the ﬁnal CL composition is achieved in
vivo and which (genetic or environmental) factors play a role in this
process is an important step toward the understanding of CL
metabolism and is also an essential step for the development of
therapeutic strategies for BTHS.
4.3. Tafazzin mRNA expression—BTHS patients
There is no apparent correlation between the genotype and clinical
phenotype of BTHS patients [42]. Missing parameters in thegenotype/phenotype comparison are tafazzin mRNA levels, protein
levels, and enzymatic activities. Although some data are beginning to
emerge, both quantitative protein analysis by immunoblotting and
enzymatic activity measurements are still hampered by aforemen-
tioned experimental difﬁculties. As we developed a quantitative
mRNA analysis for the different tafazzin splice variants we could now
compare the mRNA levels in cells and/or tissues of control subjects
and BTHS patients and at least determine whether such a correlation
exists between the mRNA levels and, if known, the genotype. For
instance, some tafazzin mutations may lead to increased transcription
or (selective) degradation of instable mRNAs. As shown in Fig. 6A,
tafazzin is equally expressed in all control ﬁbroblasts. In BTHS
ﬁbroblasts, which were all diagnosed with BTHS based on an
abnormal CL proﬁle (see Table 1 for available mutations), it appears
that in some patients total tafazzin expression is higher. This increased
expression in BTHS ﬁbroblasts may be caused by transcriptional
upregulation in order to compensate for the loss of functional enzyme
due to the mutations in the TAZ gene. In two patients (TAZ005 and
TAZ007) no tafazzin mRNA could be detected (unfortunately the
genotype of these patients is unknown) and one patient showed an
approximate reduction of 50% of tafazzin mRNA (TAZ013). This
reduction is likely caused by reducedmRNA stability and/or increased
degradation because of the aberrant splicing of exon2 due to the splice
acceptor mutation of this patient. Interestingly, two patients with the
same genotype (TAZ003 and TAZ006) displayed different total
tafazzin mRNA levels and the patient having a nonsense mutation
(TAZ001) in exon2 did not have reduced tafazzin mRNA levels, as
frequently observed in case of nonsense mutations [55]. Tafazzin
mRNA levels appeared to be severely reduced in patient TAZ002, but
this is because the splice acceptor mutation of this patient leads to
aberrant splicing of exon3, which is where part of the forward primer
anneals.
Because several tafazzin mRNA variants have been described and it
is still unknown which of these variants are relevant in vivo and
whether tafazzin mutations in BTHS inﬂuence the variant mRNA
distribution, we developed speciﬁc primer sets for each variant and
analyzed the speciﬁc expression proﬁle in control and BTHS
ﬁbroblasts. All tafazzin variants were clearly detectable in the different
control ﬁbroblasts, except the variant lacking exon6,7, which was less
abundant (Fig. 6B). The expression proﬁle in control ﬁbroblasts was
highly similar to that found in human tissues (Fig. 5). In the ﬁbroblasts
of patients TAZ005 and TAZ007 (almost) no tafazzin splice variant
mRNA was detected (Fig. 6C), conﬁrming the lack of total tafazzin
transcripts (Fig. 6A). In addition, the 50% reduction in tafazzin mRNA
of patient TAZ013 was conﬁrmed by the splice variant analysis, which
showed a 50% reduction of all variants. In patient TAZ002 (in which
the total tafazzin mRNA was not detectable due to the speciﬁc
mutation of this patient) most tafazzin mRNA variants were normally
detected, except for the variants lacking exon6,7 and exon5,6,7, both of
which also require exon3 for normal primer annealing.
Interestingly, it seems that the relative abundance of the TAZ
transcripts in ﬁbroblasts from some BTHS patients is different when
compared to control ﬁbroblasts. Like in human tissues (Fig. 5A), we
observed that tafazzin lacking exon7 is the most abundant mRNA
variant in control ﬁbroblasts, followed by the other variants with the
exception of tafazzin lacking exon6,7, which was very low. In contrast,
ﬁbroblasts from most BTHS patients showed expression levels of
tafazzin lacking exon5 and full-length tafazzin that were identical or
higher than the expression of tafazzin lacking exon7 (Fig. 6), which
could be a result of preferential splicing and/or stabilization of these
messages. The fact that these two variants have been shown to be
functional with respect to CL metabolism suggests that they are
selected to maximize residual CL remodeling activity. Although this
analysis was not performed to investigate the genotype/clinical
phenotype correlation, mRNA expression proﬁles may represent an
additional piece in this complicated jigsaw puzzle if more patients are
Fig. 5. Tafazzin mRNA tissue distribution. mRNA abundance of tafazzin splice variants in human tissues. mRNA levels are in arbitrary units, however, they can be directly compared
because the PCR efﬁciency of the different primer sets was identical and the cDNAwas normalized based on four housekeeping genes by the manufacturer. Data aremean±standard
deviation of three separate PCR reactions. He=heart, Br=brain, Pl=placenta, Lu=Lung, Li=liver, Mu=skeletal muscle, Ki=kidney, Pa=pancreas, Sp=spleen, Th=thymus,
Pr=prostate, Te=testis, Ov=ovary, In=small intestine, Co=colon, Le=leukocytes.
2010 R.H. Houtkooper et al. / Biochimica et Biophysica Acta 1788 (2009) 2003–2014analyzed with known geno- and phenotypes. Obviously, additional
investigations are needed using an antibody against human tafazzin or
an enzymatic assay for human tafazzin to further establish the
relevance of the increased expression of these variants.
4.4. Tafazzin functionality
Since the discovery in 1996 of tafazzin as the causative gene for
BTHS [28], it has remained elusive what the role is of the various
tafazzin splice variants. By expression of the different variants in the
tafazzin-deﬁcient yeast mutant, we showed that only the variant
lacking exon5 was able to fully restore the growth deﬁciency and CL
proﬁle of the mutant [31]. The human full-length tafazzin, however,
partially restored the CL abnormalities but not the growth phenotype,
and expression of the other variants resulted in no restoration at all
[31]. Re-analyses of these samples using our new HPLC–MS system
followed by closer examination of the data revealed some interesting
novel aspects worth mentioning here, especially now that the
enzymatic function of tafazzin is being unraveled. We performed a
comparison between the yeast tafazzin deletion mutant tazΔtransformed with vehicle only, tazΔ transformed with full-length
human tafazzin and tazΔ transformed with tafazzin lacking exon5
(Fig. 7). Expression of tafazzin lacking exon5 clearly led to restoration
of CL species containing multiple C18:1 acyl chains (C70 (where C70
denotes the total number of carbon atoms of the combined acyl
chains, with the most likely composition of 3×C18+1×C16 acyl
chains) and C72 (most likely 4×C18) clusters), which were virtually
absent in tazΔ transformed with full-length tafazzin. In contrast, full-
length tafazzin fully restored the CL species containing multiple C16
acyl chains (C58 to C64 clusters), which were only partially restored
by tafazzin lacking exon5. Based on these observations it appears that
tafazzin lacking exon5 preferentially incorporates C18:1 acyl chains,
whereas full-length tafazzin incorporates C16 acyl chains, either
because C16 is its preferred substrate or because it is unable to
incorporate C18. Direct determination of the substrate speciﬁcity of
these two tafazzins will hopefully clarify thematter. It should be noted
that the partial restoration of the C16-enriched CL species was not
sufﬁcient to restore the growth phenotype of tazΔ [31] suggesting that
these CL species are not functional and C18-enriched species are
required in yeast.
Fig. 6. Tafazzin mRNA in control and BTHS ﬁbroblasts. (A) Total tafazzin mRNA expression in control and BTHS ﬁbroblasts. The primer set was designed to detect all tafazzin variants
irrespective of the alternatively spliced exons. (B) mRNA expression of the individual tafazzin splice variants in control ﬁbroblasts. (C) mRNA expression of the tafazzin splice variants
in BTHS ﬁbroblasts. The mean±standard deviation of the 5 controls is given for comparison. Levels of total tafazzin mRNA transcripts (A) as well as the variants lacking exon6,7 and
exon5,6,7 (B) in BTHS patient TAZ002 (see #) are low. This is likely caused by the splice acceptor mutation of this patient. This mutation probably results in deletion of exon3 on
which the respective forward primers anneal. Data are mean±standard deviation of three separate PCR reactions.
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tafazzin lacking exon5 also resulted in the formation of CL species
containing short (C12 and C14) acyl chains (see inset, CL clusters C52
to C56). At this timewe do not have an explanation for the presence of
these small CL species, which in retrospect were also present in the
previous expression studies [31].
Maybe the most remarkable aspect of the human tafazzin
expression studies in the yeast mutant is that CL is restored to yeast
CL (i.e. containing 18:1) and not human CL which primarily contains
18:2. The availability of substrates, i.e. the fatty acyl composition of
available lipids, apparently dictates the formation of certain CL species
whereas the selectivity of the tafazzin enzyme is less important or that
tafazzin is not speciﬁc at all. Although the complementation
experiments in yeast support the function of human tafazzin in CL
remodeling, there is still no experimental evidence that directly shows
that expression of human tafazzins in BTHS cells results in restoration
of the CL proﬁle. We therefore expressed the most relevant tafazzin
splice variants in BTHS patient ﬁbroblasts. Three days after transfec-
tion no effect was observed on CL levels and composition (data not
shown). Because it has been described that the turnover of CL is very
low [56], we hypothesized that the 3-day expression could be too
short to remodel the CL pool. In order to verify this, we transfected the
tafazzin variants in BTHS patient ﬁbroblasts and used antibiotic
selection for 10 days to enrich the number of transfected cells and
allow remodeling to occur, and we measured CL and MLCL in these
cells. Expression of tafazzins was conﬁrmed by Western blot analysis
(Fig. 8, using one of the many antibodies that only detects over-
expressed tafazzin). Expression of tafazzin lacking exon5 (thepresumed active variant) resulted in a marked decrease in the
MLCL/CL ratio (Fig. 8), which is used as a diagnostic marker for
BTHS [35]. The MLCL/CL ratio was not restored to control levels
indicating that 10-day expression was still not sufﬁcient, which was
also conﬁrmed by the lack of restoration of the acyl chain composition.
Expression of either full-length tafazzin (presumed semi-active
variant) or tafazzin lacking exon7 (presumed inactive variant) also
seemed to result in a small decrease in the MLCL/CL ratio (Fig. 8).
Although this was signiﬁcant within the experiment (when compared
to themock transfection) we doubt that this reduction of theMLCL/CL
ratio truly reﬂects functionality of these two variants. Altogether, our
data suggest that tafazzin lacking exon5 most likely represents the
active tafazzin variant, but it is not excluded that the other variants
may also play a role in CL remodeling. In addition, it is clear that
transient expression of tafazzin is not sufﬁcient for the complete
remodeling of CL and that stable expression by means of viral
transduction is necessary to establish the functionality of the variants
in human BTHS cells.
4.5. Tafazzin enzymatic function
As mentioned above, tafazzin from D. melanogaster was reported
to function in the transfer of a linoleoyl acyl chain from PC to MLCL,
thereby forming CL [25]. By this means, tafazzin could function in the
enrichment of this particular acyl chain in CL. The reverse reaction,
however, in which PC is formed from lyso-PC and CL, is equally
efﬁcient [25]. This enzymatic activity could well be identical to that
described by Testet et al. for S. cerevisiae tafazzin which was thought
Fig. 7.Detailed HPLC–MS analysis of (ML)CL in yeast with andwithout expression of human tafazzins. Wild type and tazΔ yeast were transformedwith pYPGK18 and the tazΔmutant
was transformed with pYPGK18 containing either full-length human tafazzin (HTAZfull) or tafazzin lacking exon5 (HTAZ-ex5). Clusters are indicated as the number of carbon atoms
in the combined acyl chains (e.g. C70 represents all CL species which have 70 carbon atoms in the acyl chains, most likely 3×C18 and 1×C16). The tazΔ yeast mutant showed
increased MLCL levels and a shift toward more saturated acyl chains (i.e. the highest peak within a cluster is shifted to a higher m/z, an indication of less double bonds and hence a
higher degree of saturation) when compared to wild type. HTAZ-full resulted in a partial restoration of the MLCL levels and a restoration of the C16 containing CL clusters C58–C66.
The clusters that contain mainly C18 (C68–C72) are only partially or not restored at all. HTAZ-ex5 increased the incorporation of C18 in the CL clusters C68–C72, resulting in full
restoration of these CL species. The relative abundance of the C16- and C18-containing clusters (e.g. compare cluster C62 to C64) suggests that HTAZ-full preferentially incorporates
C16 in CL whereas HTAZ-ex5 preferentially incorporates C18. In HTAZ-ex5 we also observed short (likely C12- and C14-containing) CL species (C52–C56, see left inset).
2012 R.H. Houtkooper et al. / Biochimica et Biophysica Acta 1788 (2009) 2003–2014to function as a lyso-PC acyltransferase [57]. It should be noted that
the tafazzins from both D. melanogaster and S. cerevisiae are most
homologous to human tafazzin lacking exon5. Because of this, it mightbe expected that tafazzin lacking exon5 displays the same enzymatic
activity, but the role of the other tafazzins, notably full-length tafazzin,
remains to be elucidated as discussed above. Another interesting
Fig. 8. Tafazzin complementation analysis in BTHS ﬁbroblasts. Expression of human
tafazzin variants, as conﬁrmed by Western blotting, resulted in a marked reduction of
the MLCL/CL ratio, especially in the case of tafazzin lacking exon5, but not to control
levels. Data are mean±standard deviation of two individual BTHS ﬁbroblast cell lines.
As a control, BTHS and the control (MLCL/CL ratio indicated by horizontal line) were
transfected with an empty plasmid.
2013R.H. Houtkooper et al. / Biochimica et Biophysica Acta 1788 (2009) 2003–2014question that remains to be answered is how the direction of the
enzymatic reaction is regulated. If PC indeed supplies the linoleic acid
acyl chains for the tafazzin-mediated remodeling of CL, there has to be
an additional mechanism that drives themaintenance of the linoleoyl-
PC pool. Lyso-PC acyltransferases speciﬁc for linoleic acid could fulﬁll
this role by functioning as an important regulator and it would be
interesting to see whether such proteins are indeed involved in CL
remodeling.
5. Discussion and future perspectives
Since the identiﬁcation of BTHS as a primary CL remodeling
disorder caused by mutations in the tafazzin gene, CL and tafazzin
have received increasing attention. Despite the increased research
effort many questions remain, especially in relation to BTHS. The
most prominent gaps are the genotype–phenotype relation and the
pathogenesis of BTHS, which are both still poorly understood. In
order to answer these questions it will be of great value to know the
exact function of the human tafazzin and its variants. The develop-
ment of an enzymatic assay speciﬁc for tafazzin and the determina-
tion of its substrate preference are crucial and hopefully will provide
a link in resolving the relation between genotype and phenotype.
Another important tool that is obviously needed to enhance the
experimental possibilities is a proper tafazzin antibody which can
detect endogenous tafazzin (and if appropriate; different speciﬁc
variants). For instance, the interactions of yeast tafazzin that were
recently reported could be veriﬁed in human cells [11]. Another key
in understanding the genotype–phenotype relation and the
pathogenesis of BTHS is the identiﬁcation of so-called modifying
factors. Obvious candidate proteins inﬂuencing the genotype–
phenotype relation and the diverse pathology of BTHS patients
include proteins involved in oxidative phosphorylation, apoptosis
and oxidative stress defense, as was recently suggested [58].
Proteins involved in mitochondrial import could also play a role
in these processes as stressed by the identiﬁcation of a BTHS-like
disorder, which is caused by mutations in the mitochondrial import
protein TIM14 [59].
Another interesting avenue for future research is the regulation of
CL metabolism, notably the tafazzin-mediated CL remodeling.
Although some studies were performed that showed that CL
metabolism is transcriptionally regulated [60–62], not much is
known about the regulation of CL synthesis and remodeling and
whether this could be used as a potential treatment target for BTHS
patients.Currently usedmodel systems for BTHS include yeast, ﬂy and zebra
ﬁsh. Although all these models have proven to be (and still are) very
useful, one obvious missing model system is the tafazzin-deﬁcient
mouse. The generation of a mammalian model for BTHS is crucial in
order to resolve the questions mentioned above but also to test
possible therapeutic options for this frequently lethal disorder.
6. Final remarks
During the evaluation of this manuscript two important papers
appeared addressing lipase activities directed toward CL. The ﬁrst
paper describes a newly identiﬁed lipase in yeast (YGR110w or
cardiolipin-speciﬁc deacylase 1 (CLD1)) that speciﬁcally deacylates
palmitoyl acyl chains from CL [63]. The cld1Δ yeast mutant clearly
shows a lower degree of unsaturation in CL. Additionally, it was shown
that deletion of CLD1 in the tazΔ background suppressed the
accumulation of MLCL and restored the CL content to wild type levels.
Although not mentioned in the paper, it is likely that CL of the cld1Δ
tazΔ double mutant contains mostly saturated acyl chains, which is
why growth of this mutant on non-fermentable carbon sources is not
restored [63]. These results suggest that the defective CL composition
and not the MLCL accumulation is the cause of the mitochondrial
dysfunction and phenotype observed after tafazzin deﬁciency, at least
in yeast. The second paper on lipase function in relation to CL
remodeling concerns the function of the calcium-independent
phospholipase A2 (iPLA2) [64]. Deletion of iPLA2 in the D. melanoga-
ster tazΔ mutant resulted in a 50% reduction of the MLCL/CL ratio,
which was accompanied by a ∼70% restoration of male ﬂy fertility.
Treatment of BTHS lymphoblasts with the iPLA2 inhibitor bromoenol
lactone also resulted in a clear reduction of the MLCL/CL ratio,
although the functional consequences of this decrease were not
assessed [64]. How the activities described in these papers relate to
the previously described function of tafazzin as a transacylase that
does not require deacylation remains an open question and should be
clariﬁed in future studies.
Acknowledgements
We thank Dr. A. Metzenberg for providing the tafazzin antibody
and Henk van Lenthe and Femke Stet for technical assistance. This
work is supported by a grant from the Prinses Beatrix Fonds (Grant
Number WAR05-0126) to F.M.V. and grants from the Barth Syndrome
Foundation to W.K. and F.M.V.
References
[1] G. Daum, Lipids of mitochondria, Biochim. Biophys. Acta 822 (1985) 1–42.
[2] V.E. Kagan, V.A. Tyurin, J. Jiang, Y.Y. Tyurina, V.B. Ritov, A.A. Amoscato, A.N. Osipov,
N.A. Belikova, A.A. Kapralov, V. Kini, VlasovaII , Q. Zhao, M. Zou, P. Di, D.A.
Svistunenko, I.V. Kurnikov, G.G. Borisenko, Cytochrome c acts as a cardiolipin
oxygenase required for release of proapoptotic factors, Nat. Chem. Biol. 1 (2005)
223–232.
[3] F. Gonzalvez, Z.T. Schug, R.H. Houtkooper, E.D. MacKenzie, D.G. Brooks, R.J.
Wanders, P.X. Petit, F.M. Vaz, E. Gottlieb, Cardiolipin provides an essential
activating platform for caspase-8 on mitochondria, J. Cell Biol. 183 (2008)
681–696.
[4] M. Lutter, M. Fang, X. Luo, M. Nishijima, X. Xie, X. Wang, Cardiolipin provides
speciﬁcity for targeting of tBid to mitochondria, Nat. Cell Biol. 2 (2000) 754–761.
[5] R.H. Houtkooper, F.M. Vaz, Cardiolipin, the heart of mitochondrial metabolism,
Cell. Mol. Life Sci. 65 (2008) 2493–2506.
[6] H. Boumans, L.A. Grivell, J.A. Berden, The respiratory chain in yeast behaves as a
single functional unit, J. Biol. Chem. 273 (1998) 4872–4877.
[7] K. Brandner, D.U. Mick, A.E. Frazier, R.D. Taylor, C. Meisinger, P. Rehling, Taz1, an
outer mitochondrial membrane protein, affects stability and assembly of inner
membrane protein complexes: Implications for Barth Syndrome, Mol. Biol. Cell 16
(2005) 5202–5214.
[8] M. McKenzie, M. Lazarou, D.R. Thorburn, M.T. Ryan, Mitochondrial respiratory
chain supercomplexes are destabilized in Barth Syndrome patients, J. Mol. Biol.
361 (2006) 462–469.
[9] B. Hoffmann, A. Stockl, M. Schlame, K. Beyer, M. Klingenberg, The reconstituted
ADP/ATP carrier activity has an absolute requirement for cardiolipin as shown in
cysteine mutants, J. Biol. Chem. 269 (1994) 1940–1944.
2014 R.H. Houtkooper et al. / Biochimica et Biophysica Acta 1788 (2009) 2003–2014[10] S.M. Claypool, Y. Oktay, P. Boontheung, J.A. Loo, C.M. Koehler, Cardiolipin deﬁnes
the interactome of the major ADP/ATP carrier protein of the mitochondrial inner
membrane, J. Cell. Biol. 182 (2008) 937–950.
[11] S.M. Claypool, P. Boontheung, J.M. McCaffery, J.A. Loo, C.M. Koehler, The cardiolipin
transacylase, tafazzin, associates with two distinct respiratory components
providing insight into Barth syndrome, Mol. Biol. Cell. 19 (2008) 5143–5155.
[12] T.H. Haines, N.A. Dencher, Cardiolipin: A proton trap for oxidative phosphoryla-
tion, FEBS Lett. 528 (2002) 35–39.
[13] F. Gonzalvez, E. Gottlieb, Cardiolipin: Setting the beat of apoptosis, Apoptosis 12
(2007) 877–885.
[14] A.S. Joshi, J. Zhou, V.M. Gohil, S. Chen, M.L. Greenberg, Cellular functions of
cardiolipin in yeast, Biochim. Biophys. Acta 1793 (2009) 212–218.
[15] A.J. Chicco, G.C. Sparagna, Role of cardiolipin alterations in mitochondrial
dysfunction and disease, Am. J. Physiol. Cell Physiol. 292 (2007) C33–44.
[16] M. Schlame, Cardiolipin synthesis for the assembly of bacterial and mitochondrial
membranes, J. Lipid Res. 49 (2008) 1607–1620.
[17] K.Y. Hostetler, J.M. Galesloot, P. Boer, H. Van Den Bosch, Further studies on the
formation of cardiolipin and phosphatidylglycerol in rat liver mitochondria. Effect
of divalent cations and the fatty acid composition of CDP-diglyceride, Biochim.
Biophys. Acta 380 (1975) 382–389.
[18] R.H. Houtkooper, H. Akbari, H. van Lenthe, W. Kulik, R.J. Wanders, M. Frentzen,
F.M. Vaz, Identiﬁcation and characterization of human cardiolipin synthase,
FEBS Lett. 580 (2006) 3059–3064.
[19] M. Nowicki, F. Muller, M. Frentzen, Cardiolipin synthase of Arabidopsis thaliana,
FEBS Lett. 579 (2005) 2161–2165.
[20] W.E. Lands, Metabolism of glycerolipids. 2. The enzymatic acylation of
lysolecithin, J. Biol. Chem. 235 (1960) 2233–2237.
[21] Y. Xu, R.I. Kelley, T.J. Blanck, M. Schlame, Remodeling of cardiolipin by
phospholipid transacylation, J. Biol. Chem. 278 (2003) 51380–51385.
[22] B.J. Ma, W.A. Taylor, V.W. Dolinsky, G.M. Hatch, Acylation of monolysocardiolipin
in rat heart, J. Lipid Res. 40 (1999) 1837–1845.
[23] W.A. Taylor, G.M. Hatch, Puriﬁcation and characterization of monolysocardiolipin
acyltransferase from pig liver mitochondria, J. Biol. Chem. 278 (2003)
12716–12721.
[24] M. Schlame, B. Rustow, Lysocardiolipin formation and reacylation in isolated rat
liver mitochondria, Biochem. J. 272 (1990) 589–595.
[25] Y. Xu, A. Malhotra, M. Ren, M. Schlame, The enzymatic function of tafazzin, J. Biol.
Chem. 281 (2006) 39217–39224.
[26] P.G. Barth, H.R. Scholte, J.A. Berden, J.M. Van der Klei-Van Moorsel, I.E. Luyt-
Houwen, E.T. Van 't Veer-Korthof, J.J. Van der Harten, M.A. Sobotka-Plojhar, An X-
linked mitochondrial disease affecting cardiac muscle, skeletal muscle and
neutrophil leucocytes, J. Neurol. Sci. 62 (1983) 327–355.
[27] C.T. Spencer, R.M. Bryant, J. Day, I.L. Gonzalez, S.D. Colan, W.R. Thompson, J. Berthy,
S.P. Redfearn, B.J. Byrne, Cardiac and clinical phenotype in Barth syndrome,
Pediatrics 118 (2006) e337–346.
[28] S. Bione, P. D'Adamo, E. Maestrini, A.K. Gedeon, P.A. Bolhuis, D. Toniolo, A novel X-
linked gene, G4.5. is responsible for Barth syndrome, Nat. Genet. 12 (1996)
385–389.
[29] F. Valianpour, V. Mitsakos, D. Schlemmer, J.A. Towbin, J.M. Taylor, P.G. Ekert, D.R.
Thorburn, A. Munnich, R.J. Wanders, P.G. Barth, F.M. Vaz, Monolysocardiolipins
accumulate in Barth syndrome but do not lead to enhanced apoptosis, J. Lipid Res.
46 (2005) 1182–1195.
[30] M.A. van Werkhoven, D.R. Thorburn, A.K. Gedeon, J.J. Pitt, Monolysocardiolipin in
cultured ﬁbroblasts is a sensitive and speciﬁc marker for Barth Syndrome, J. Lipid
Res. 47 (2006) 2346–2351.
[31] F.M. Vaz, R.H. Houtkooper, F. Valianpour, P.G. Barth, R.J. Wanders, Only one splice
variant of the human TAZ gene encodes a functional protein with a role in
cardiolipin metabolism, J. Biol. Chem. 278 (2003) 43089–43094.
[32] P. Vreken, F. Valianpour, L.G. Nijtmans, L.A. Grivell, B. Plecko, R.J. Wanders, P.G.
Barth, Defective remodeling of cardiolipin and phosphatidylglycerol in Barth
syndrome, Biochem. Biophys. Res. Commun. 279 (2000) 378–382.
[33] Y. Xu, M. Condell, H. Plesken, I. Edelman-Novemsky, J. Ma, M. Ren, M. Schlame, A
Drosophila model of Barth syndrome, Proc. Natl. Acad. Sci. U. S. A. 103 (2006)
11584–11588.
[34] R.H. Houtkooper, R.J. Rodenburg, C. Thiels, H. van Lenthe, F. Stet, B.T. Poll-The, J.E.
Stone, C.G. Steward, R.J. Wanders, J. Smeitink, W. Kulik, F.M. Vaz, Cardiolipin and
monolysocardiolipin analysis in ﬁbroblasts, lymphocytes, and tissues using high-
performance liquid chromatography–mass spectrometry as a diagnostic test for
Barth syndrome, Anal. Biochem. 387 (2009) 230–237.
[35] W. Kulik, H. van Lenthe, F.S. Stet, R.H. Houtkooper, H. Kemp, J.E. Stone, C.G.
Steward, R.J. Wanders, F.M. Vaz, Bloodspot assay using HPLC-tandem mass
spectrometry for detection of Barth syndrome, Clin. Chem. 54 (2008) 371–378.
[36] M.R. Schmidt, N. Birkebaek, I. Gonzalez, L. Sunde, Barth syndrome without 3-
methylglutaconic aciduria, Acta. Paediatr. 93 (2004) 419–421.
[37] P.G. Barth, F. Valianpour, V.M. Bowen, J. Lam, M. Duran, F.M. Vaz, R.J. Wanders, X-
linked cardioskeletal myopathy and neutropenia (Barth syndrome): An update,
Am. J. Med. Genet. A 126A (2004) 349–354.
[38] D. Acehan, Y. Xu, D.L. Stokes, M. Schlame, Comparison of lymphoblast
mitochondria from normal subjects and patients with Barth syndrome using
electron microscopic tomography, Lab. Invest. 87 (2007) 40–48.[39] S. Dimauro, G. Davidzon, Mitochondrial DNA and disease, Ann. Med. 37 (2005)
222–232.
[40] D.C. Wallace, Mitochondrial diseases in man and mouse, Science 283 (1999)
1482–1488.
[41] B.J. van Raam, W. Sluiter, E. de Wit, D. Roos, A.J. Verhoeven, T.W. Kuijpers,
Mitochondrial membrane potential in human neutrophils is maintained by
complex III activity in the absence of supercomplex organisation, PLoS ONE 3
(2008) e2013.
[42] J. Johnston, R.I. Kelley, A. Feigenbaum, G.F. Cox, G.S. Iyer, V.L. Funanage, R.
Proujansky, Mutation characterization and genotype-phenotype correlation in
Barth syndrome, Am. J. Hum. Genet. 61 (1997) 1053–1058.
[43] M.C. Pangborn, Isolation and puriﬁcation of a serologically active phospholipid
from beef heart, J. Biol. Chem. 143 (1942) 247–256.
[44] M. Schlame, J.A. Towbin, P.M. Heerdt, R. Jehle, S. DiMauro, T.J. Blanck, Deﬁciency of
tetralinoleoyl-cardiolipin in Barth syndrome, Ann. Neurol. 51 (2002) 634–637.
[45] M. Schlame, M. Ren, Y. Xu, M.L. Greenberg, I. Haller, Molecular symmetry in
mitochondrial cardiolipins, Chem. Phys. Lipids 138 (2005) 38–49.
[46] H. Cheng, D.J. Mancuso, X. Jiang, S. Guan, J. Yang, K. Yang, G. Sun, R.W. Gross, X.
Han, Shotgun lipidomics reveals the temporally dependent, highly diversiﬁed
cardiolipin proﬁle in the mammalian brain: Temporally coordinated postnatal
diversiﬁcation of cardiolipin molecular species with neuronal remodeling,
Biochemistry 47 (2008) 5869–5880.
[47] M. Schlame, Assays of cardiolipin levels, Methods Cell Biol. 80 (2007) 223–240.
[48] E.G. Bligh, W.J. Dyer, A rapid method of total lipid extraction and puriﬁcation, Can.
J. Biochem. Physiol. 37 (1959) 911–917.
[49] J. Folch, M. Lees, G.H. Sloane Stanley, A simple method for the isolation and
puriﬁcation of total lipids from animal tissues, J. Biol. Chem. 226 (1957) 497–509.
[50] T.A. Garrett, R. Kordestani, C.R. Raetz, Quantiﬁcation of cardiolipin by liquid
chromatography–electrospray ionization mass spectrometry, Methods Enzymol.
433 (2007) 213–230.
[51] X. Han, R.W. Gross, Shotgun lipidomics: Electrospray ionization mass spectro-
metric analysis and quantitation of cellular lipidomes directly from crude extracts
of biological samples, Mass Spectrom. Rev. 24 (2005) 367–412.
[52] G.C. Sparagna, C.A. Johnson, S.A. McCune, R.L. Moore, R.C. Murphy, Quantitation of
cardiolipinmolecular species in spontaneously hypertensive heart failure rats using
electrospray ionization mass spectrometry, J. Lipid Res. 46 (2005) 1196–1204.
[53] F.F. Hsu, J. Turk, E.R. Rhoades, D.G. Russell, Y. Shi, E.A. Groisman, Structural
characterization of cardiolipin by tandem quadrupole and multiple-stage
quadrupole ion-trap mass spectrometry with electrospray ionization, J. Am. Soc.
Mass. Spectrom. 16 (2005) 491–504.
[54] I.L. Gonzalez, Barth syndrome: TAZ gene mutations, mRNAs, and evolution, Am. J.
Med. Genet. A 134 (2005) 409–414.
[55] Y.F. Chang, J.S. Imam, M.F. Wilkinson, The nonsense-mediated decay RNA
surveillance pathway, Annu. Rev. Biochem. 76 (2007) 51–74.
[56] C. Landriscina, F.M. Megli, E. Quagliariello, Turnover of fatty acids in rat liver
cardiolipin: Comparisonwith othermitochondrial phospholipids, Lipids 11 (1976)
61–66.
[57] E. Testet, J. Laroche-Traineau, A. Noubhani, D. Coulon, O. Bunoust, N. Camougrand,
S. Manon, R. Lessire, J.J. Bessoule, Ypr140wp, “the yeast tafazzin”, displays a
mitochondrial lysophosphatidylcholine (lyso-PC) acyltransferase activity related
to triacylglycerol and mitochondrial lipid synthesis, Biochem. J. 387 (2005)
617–626.
[58] S. Chen, Q. He, M.L. Greenberg, Loss of tafazzin in yeast leads to increased oxidative
stress during respiratory growth, Mol. Microbiol. 68 (2008) 1061–1072.
[59] K.M. Davey, J.S. Parboosingh, D.R. McLeod, A. Chan, R. Casey, P. Ferreira, F.F. Snyder,
P.J. Bridge, F.P. Bernier, Mutation of DNAJC19, a human homologue of yeast inner
mitochondrial membrane co-chaperones, causes DCMA syndrome, a novel
autosomal recessive Barth syndrome-like condition, J. Med. Genet. 43 (2006)
385–393.
[60] Y. Athea, B. Viollet, P. Mateo, D. Rousseau, M. Novotova, A. Garnier, S. Vaulont, J.R.
Wilding, A. Grynberg, V. Veksler, J. Hoerter, R. Ventura-Clapier, AMP-activated
protein kinase alpha2 deﬁciency affects cardiac cardiolipin homeostasis and
mitochondrial function, Diabetes 56 (2007) 786–794.
[61] G.M. Hatch, Cell biology of cardiac mitochondrial phospholipids, Biochem. Cell.
Biol. 82 (2004) 99–112.
[62] Y.J. Jiang, B. Lu, F.Y. Xu, J. Gartshore, W.A. Taylor, A.J. Halayko, F.J. Gonzalez, J.
Takasaki, P.C. Choy, G.M. Hatch, Stimulation of cardiac cardiolipin biosynthesis by
PPARalpha activation, J. Lipid Res. 45 (2004) 244–252.
[63] A. Beranek, G. Rechberger, H. Knauer, H. Wolinski, S.D. Kohlwein, R. Leber,
Identiﬁcation of a cardiolipin-speciﬁc phospholipase encoded by the gene CLD1
(YGR110W) in yeast, J. Biol. Chem. 284 (2009) 11572–11578.
[64] A. Malhotra, I. Edelman-Novemsky, Y. Xu, H. Plesken, J. Ma, M. Schlame, M. Ren,
Role of calcium-independent phospholipase A2 in the pathogenesis of Barth
syndrome, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 2337–2341.
[65] M.M. Bradford, A rapid and sensitive method for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem.
72 (1976) 248–254.
[66] C. Ramakers, J.M. Ruijter, R.H. Deprez, A.F. Moorman, Assumption-free analysis of
quantitative real-time polymerase chain reaction (PCR) data, Neurosci. Lett. 339
(2003) 62–66.
